

PROMOTION RECOMMENDATION
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
DEPARTMENT OF SURGERY

Weiping Zou, M.D., Ph.D., Associate Professor of Surgery, with tenure, Department of Surgery, Medical School, is recommended for promotion to Professor of Surgery, with tenure, Department of Surgery, Medical School.

Academic Degrees:

Ph.D.	1997	University of Paris, France
M.D.	1990	Tongji Medical School, China
B.S.	1987	Tongji Medical School, China

Professional Record:

2006-present	Associate Professor of Surgery, University of Michigan
2004-2006	Associate Professor of Medicine, Tulane University
2001-2004	Assistant Professor of Surgery, Tulane University

Summary of Evaluation:

Teaching: Dr. Weiping Zou is actively involved with teaching sectional seminars, departmental seminars, graduate student programs, cancer center seminars, and FACS & FACSria training seminars. Dr. Zou teaches clinical fellows, physicians, and research staff. He currently has postdoctoral students, graduate students and is a mentor for junior faculty. He also trains grant and technical consultants. He is currently a member of the Surgical Oncology Research T32 training grant as well as the Cell and Molecular Dermatology T32 grant and the Michigan Graduate Program in Immunology.

Dr. Zou serves on the University of Michigan Immunology Graduate Program Exam Committee, Graduate Student Affairs Committee, Department of Surgery Research Advisory Committee, and is a member of the NIH Faculty Intramural Evaluation Committee. He was the Chair and organizer of the Th17/Treg Symposium on October 17, 2007, University of Michigan. Dr. Zou also serves as consultant and/or collaborator for UM faculty grant applications; non-UM grant applications, and industry type grants, i.e. Unither and Virium Pharmaceuticals.

Research: Dr. Zou is making major contributions to literature. He has contributed over 46 peer-reviewed publications. He is author or co-author on three book chapters, with four more in press. Dr. Zou has in submission two patents. In addition, Dr. Zou has a significant number of national and international research awards including the Charles B. Henriques Award for Excellence in Research in 2005 and the Presidential Award at Tulane in 2004. He has been awarded a Travel Award, The 5th Bienial Ovarian Cancer Research Symposium (Seattle, 2004), the Tulane Outstanding Research Excellence, THUSC Board of Governors (2003 & 2004), Mauvernay Research Excellence, at Tulane University (Finalist in 2003 and 1st Prize in 2004), Research Excellent for Women's Health; Role: Mentor for the award recipient (2004), Outstanding Young Faculty Award, American Federation for Medical Research (2002), Finalist

in Outstanding Scientist Competition, Greater Asian American Chamber of Commerce, Dallas Texas (1999), Scholarship from SIDACTION, France (1998-1997), Fellowship from ANRS, France (1997-1994), Visiting scholarship from Claude Bernard Association, France (1994-1993), Prize for Achievement in Scientific Research, Committee on Education of Hubei (1986).

Dr. Zou has a solid track record for funded peer-reviewed grant support. He is principal investigator on five NCI/NIH grants which include the following: R01 NCI, CA123088 (ends 2012), R01 NCI, CA092562 (ends 2008), R01 NCI, CA099985 (ends 2009). He is also principal investigator for two pharmaceutical grants; Unither Research gift, Unither Pharmaceuticals, and OVA-Gy-18 treatment in ovarian cancers, Unither Pharmaceuticals (ends 2010). He has six pending grants from the National Cancer Institute and the National Institute of Health (R01 and P01). In addition, Dr. Zou has 72 scientific presentations, national and international conferences.

Recent and Significant Publications:

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, and Zou W: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *J Exp Med* 203:871-881, 2006.

Kryczek I, Wei S, Zou L, Altuwajri S, Szeliga W, Kolls J, Chang A, and Zou W: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. *J Immunol* 178:6730-6733, 2007.

Kryczek, I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, and Zou W: Cutting edge: Opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool: IL-1 subverts IL-2-mediated suppression. *J Immunol* 179:1423-1426, 2007.

Wei, S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, Herberman RB, and Zou W: Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. *Cancer Res* 67:7487-7494, 2007.

Kryczek, I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, and Zou W: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. *Cancer Res* 67:8900-8905, 2007.

Service: Dr. Zou has an excellent record of service not only to the University of Michigan, but nationally as well. He is a member of a number of important research societies; American Association for Cancer Research, American Association of Immunologists, the International Society for Biological Therapy of cancer, and the International Cancer Microenvironment Society. Dr. Zou is a reviewer for more than ten funding agencies and 20 journals. He most recently became the Associate Editor for the *Journal of Immunology*.

Dr. Zou is ad hoc grant reviewer on the following; NIH (USA): Cellular and Tissue Biology P01 Cluster (1/2007), NIH (USA): Transplantation, Tolerance, and Tumor Immunology (TTT) (10/2006), Tumor Microenvironment (TMN) (2006), Immunity and Host Defense (IHD)

(02/2005), Department of Defense (USA) (Ovarian Cancer Panel) (2004-), Alliance for cancer gene therapy (USA) (2005), Israel Science Foundation (2005), Cancer Research UK (2005), Swiss National Science Foundation (2005-), Austrian Genome Research Program (GEN-AU) (2005), and Institut National du Cancer (INCa) (French National Cancer Institute) (2005).

External Review:

Reviewer A: “Dr. Zou is an exceptionally able scientist, who has made seminal contributions to cancer research, primarily by demonstrating the crucial role of regulatory T cells (Treg) in the escape of tumors from immunological control and indicating ways by which this problem can be overcome. These findings are likely to revolutionize the field of therapeutic tumor vaccines...”

Reviewer B: “Dr. Zou has become one of the leading authorities in the field of tumor immunology. One of his most important contributions is on human tumor regulatory T cells and immunosuppressive networks in the tumor microenvironment. This part of his work has profoundly reshaped the field of human tumor immunology and shifted the paradigm of human tumor immunotherapy...”


Reviewer C: “Overall, I would rank him in the top 1% to 2% of cancer researcher’s nationally with respect to productivity, impact, and professional standing.”

Reviewer D: “Dr. Zou is a highly sought after speaker both nationally and internationally....He is always willing to help other investigators and has developed many valuable and productive collaborations during his career.”

Reviewer E: “I have been considerably impressed by his broad knowledge of immunology. I consider Weiping to be an excellent scientist whose...thoughtful and methodical approach to science, makes him an invaluable asset to any laboratory.”

Summary of Recommendation:

Dr. Weiping Zou is well respected by his colleagues and known to be an outstanding scientist. Dr. Zou is a highly dedicated researcher, devoted to service, and education. I strongly recommend him for promotion to Professor, with tenure, in the Department of Surgery.



James O. Woolliscroft, M.D.

Dean

Lyle C. Roll Professor of Medicine

May 2008